Referred to the House Committee on the Judiciary.
The Skinny Labels, Big Savings Act amends 35 U.S.C. §271 to create an express safe harbor from direct, induced, or contributory infringement for method-of-use patent claims when a drug or biological product applicant seeks approval or markets a product with labeling that omits the patented condition(s) of use. The safe harbor covers ANDA (505(j)), 505(b)(2), certain 512(b)(2) applications, and biosimilar applications under 351(k), and allows submitting for approval, describing products as generic/biosimilar, and promoting or commercially marketing products so long as the labeling, promotion, or marketing does not reference the patented indications that were disclosed to FDA and the labeling does not include those conditions.
Effect on drug prices vs. effect on innovation: progressives emphasize price/access gains; conservatives emphasize weakened patent incentives and property rights.
Relative to its intended legislative type, this bill is a clearly focused statutory amendment that establishes a specific safe-harbor defense to infringement for certain method-of-use patent claims related to drugs and biological products, with precise textual mechanics and clear cross-references to existing statutes and regulations.
The Skinny Labels, Big Savings Act amends 35 U.S.C. §271 to create an express safe harbor from direct, induced, or contributory infringement for method-of-use patent claims when a drug or biological product applicant seeks approval or markets a product with labeling that omits the patented condition(s) of use.
The safe harbor covers ANDA (505(j)), 505(b)(2), certain 512(b)(2) applications, and biosimilar applications under 351(k), and allows submitting for approval, describing products as generic/biosimilar, and promoting or commercially marketing products so long as the labeling, promotion, or marketing does not reference the patented indications that were disclosed to FDA and the labeling does not include those conditions.
The bill defines key terms (labeling, promoting, biosimilar/interchangeable/reference product, commercial marketing) and makes the changes applicable to conduct and proceedings before, on, or after enactment.
By content alone, the bill is a narrow, well-defined change that could attract support from pro-competition and cost-containment interests and from generic manufacturers, which improves its odds relative to sweeping reforms. However, it directly alters patent-enforcement incentives for drug and biologic innovators, a sector that historically mounts effective opposition; the lack of compromise mechanisms (sunset, pilot, offset provisions) and the retroactivity provision increase contestation. These factors make enactment plausible but uncertain — easier in the House than the Senate under ordinary legislative patterns.
Relative to its intended legislative type, this bill is a clearly focused statutory amendment that establishes a specific safe-harbor defense to infringement for certain method-of-use patent claims related to drugs and biological products, with precise textual mechanics and clear cross-references to existing statutes and regulations.
Effect on drug prices vs. effect on innovation: progressives emphasize price/access gains; conservatives emphasize weakened patent incentives and property rights.
These are examples from the analysis, not a ranked list of the most-affected groups.
Effect on drug prices vs. effect on innovation: progressives emphasize price/access gains; conservatives emphasize weakened patent incentives and property rights.
A mainstream progressive would likely view this bill as broadly pro-competition and pro-consumer because it facilitates earlier generic and biosimilar entry for at least some uses, which can lower prices and expand access.
They would also flag concerns that narrowing enforceability of method-of-use patents could reduce incentives to develop new indications or fund follow-on research, and might create patient-safety risks if companies encourage off-label use.
Overall, a liberal-left actor would probably lean supportive if paired with safeguards to protect prescribers and patients and to preserve reasonable R&D incentives.
A pragmatic centrist would see clear consumer benefits from increased generic and biosimilar competition but would be cautious about unintended consequences for IP certainty, clinical incentives, and patient safety.
They would focus on practical safeguards, clear regulatory guidance from FDA, and ways to limit gaming (e.g., strict limits on promotion and clear labeling rules).
With modest amendments to address safety and to clarify boundaries, a centrist would be inclined to support the bill.
A mainstream conservative would be split: some would welcome measures that increase market competition and lower prices, while others would be concerned about weakening patent rights and property protections that support pharmaceutical innovation.
Many conservatives who emphasize intellectual property would view the bill skeptically because it narrows enforceable patent rights; those prioritizing consumer cost-reduction might be cautiously supportive if intellectual property and liability protections for innovators remain meaningful.
Overall, the conservative reaction will depend on the balance between competition and IP protection.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
By content alone, the bill is a narrow, well-defined change that could attract support from pro-competition and cost-containment interests and from generic manufacturers, which improves its odds relative to sweeping reforms. However, it directly alters patent-enforcement incentives for drug and biologic innovators, a sector that historically mounts effective opposition; the lack of compromise mechanisms (sunset, pilot, offset provisions) and the retroactivity provision increase contestation. These factors make enactment plausible but uncertain — easier in the House than the Senate under ordinary legislative patterns.
The bill has not accumulated any surfaced votes yet.
Effect on drug prices vs. effect on innovation: progressives emphasize price/access gains; conservatives emphasize weakened patent incentiv…
By content alone, the bill is a narrow, well-defined change that could attract support from pro-competition and cost-containment interests…
Relative to its intended legislative type, this bill is a clearly focused statutory amendment that establishes a specific safe-harbor defense to infringement for certain method-of-use patent claims related to drugs and…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.